アテゾリズマブ (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "アテゾリズマブ" in Japanese language version.

refsWebsite

Global rank Japanese rank

6nih.gov

4^th place

24^th place

3doi.org

2^nd place

6^th place

2mdpi.com

2,912^th place

3,058^th place

1medicines.org.uk

3,823^rd place

low place

1immuno-oncologynews.com

low place

1pmda.go.jp

6,690^th place

394^th place

1europa.eu

68^th place

425^th place

1worldcat.org

5^th place

19^th place

1creativecommons.org

1,010^th place

4,166^th place

creativecommons.org

Nasser, Nicola J.; Gorenberg, Miguel; Agbarya, Abed (November 2020). “First line Immunotherapy for Non-Small Cell Lung Cancer” (英語). Pharmaceuticals 13 (11): 373. doi:10.3390/ph13110373. PMC 7695295. PMID 33171686. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.

doi.org

Nasser, Nicola J.; Gorenberg, Miguel; Agbarya, Abed (2020-11-08). “First line Immunotherapy for Non-Small Cell Lung Cancer” (英語). Pharmaceuticals 13 (11): 373. doi:10.3390/ph13110373. ISSN 1424-8247. PMC 7695295. PMID 33171686.
Nasser, Nicola J.; Gorenberg, Miguel; Agbarya, Abed (November 2020). “First line Immunotherapy for Non-Small Cell Lung Cancer” (英語). Pharmaceuticals 13 (11): 373. doi:10.3390/ph13110373. PMC 7695295. PMID 33171686. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
“De-novo and acquired resistance to immune checkpoint targeting”. The Lancet. Oncology 18 (12): e731–e741. (December 2017). doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.

europa.eu

ema.europa.eu

“Tecentriq EPAR”. European Medicines Agency. 31 July 2020閲覧。 Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

immuno-oncologynews.com

“Genentech Presents Positive Results of Atezolizumab in Advanced Bladder Cancer”. (Oct 2, 2015)

mdpi.com

Nasser, Nicola J.; Gorenberg, Miguel; Agbarya, Abed (2020-11-08). “First line Immunotherapy for Non-Small Cell Lung Cancer” (英語). Pharmaceuticals 13 (11): 373. doi:10.3390/ph13110373. ISSN 1424-8247. PMC 7695295. PMID 33171686.
Nasser, Nicola J.; Gorenberg, Miguel; Agbarya, Abed (November 2020). “First line Immunotherapy for Non-Small Cell Lung Cancer” (英語). Pharmaceuticals 13 (11): 373. doi:10.3390/ph13110373. PMC 7695295. PMID 33171686. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.

medicines.org.uk

“Tecentriq 1,200 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC)”. (emc). 4 March 2020閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

Nasser, Nicola J.; Gorenberg, Miguel; Agbarya, Abed (2020-11-08). “First line Immunotherapy for Non-Small Cell Lung Cancer” (英語). Pharmaceuticals 13 (11): 373. doi:10.3390/ph13110373. ISSN 1424-8247. PMC 7695295. PMID 33171686.
Nasser, Nicola J.; Gorenberg, Miguel; Agbarya, Abed (November 2020). “First line Immunotherapy for Non-Small Cell Lung Cancer” (英語). Pharmaceuticals 13 (11): 373. doi:10.3390/ph13110373. PMC 7695295. PMID 33171686. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
“De-novo and acquired resistance to immune checkpoint targeting”. The Lancet. Oncology 18 (12): e731–e741. (December 2017). doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.

pmc.ncbi.nlm.nih.gov

Nasser, Nicola J.; Gorenberg, Miguel; Agbarya, Abed (2020-11-08). “First line Immunotherapy for Non-Small Cell Lung Cancer” (英語). Pharmaceuticals 13 (11): 373. doi:10.3390/ph13110373. ISSN 1424-8247. PMC 7695295. PMID 33171686.
Nasser, Nicola J.; Gorenberg, Miguel; Agbarya, Abed (November 2020). “First line Immunotherapy for Non-Small Cell Lung Cancer” (英語). Pharmaceuticals 13 (11): 373. doi:10.3390/ph13110373. PMC 7695295. PMID 33171686. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.

dailymed.nlm.nih.gov

“Tecentriq- atezolizumab injection, solution”. DailyMed (3 June 2020). 31 July 2020閲覧。

pmda.go.jp

info.pmda.go.jp

“テセントリク点滴静注840mg／テセントリク点滴静注1200mg 添付文書”. www.info.pmda.go.jp. PMDA. 2021年5月28日閲覧。

worldcat.org

search.worldcat.org

Nasser, Nicola J.; Gorenberg, Miguel; Agbarya, Abed (2020-11-08). “First line Immunotherapy for Non-Small Cell Lung Cancer” (英語). Pharmaceuticals 13 (11): 373. doi:10.3390/ph13110373. ISSN 1424-8247. PMC 7695295. PMID 33171686.